Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion.
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to
study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with
ROS1+ locally advanced/metastatic solid tumors .